BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Johncilla M, Grover S, Zhang X, Jain D, Srivastava A. Morphological spectrum of immune check-point inhibitor therapy-associated gastritis. Histopathology. 2020;76:531-539. [PMID: 31692018 DOI: 10.1111/his.14029] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 23.0] [Reference Citation Analysis]
Number Citing Articles
1 Arora K, Zhang ML, Goiburú-chenu MB, England J. Pathology of immune checkpoint inhibitor-induced injury of the gastrointestinal tract and hepatobiliary system. Diagnostic Histopathology 2021;27:62-8. [DOI: 10.1016/j.mpdhp.2020.11.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Cheung VTF, Brain O. Immunotherapy induced enterocolitis and gastritis - What to do and when? Best Pract Res Clin Gastroenterol 2020;48-49:101703. [PMID: 33317787 DOI: 10.1016/j.bpg.2020.101703] [Reference Citation Analysis]
3 Pennelli G, Grillo F, Galuppini F, Ingravallo G, Pilozzi E, Rugge M, Fiocca R, Fassan M, Mastracci L. Gastritis: update on etiological features and histological practical approach. Pathologica 2020;112:153-65. [PMID: 33179619 DOI: 10.32074/1591-951X-163] [Reference Citation Analysis]
4 Rugge M, Savarino E, Sbaraglia M, Bricca L, Malfartheiner P. Gastritis: The clinico-pathological spectrum. Dig Liver Dis 2021:S1590-8658(21)00100-6. [PMID: 33785282 DOI: 10.1016/j.dld.2021.03.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Mendo R, Figueiredo P, Mascarenhas L. Checkpoint Inhibitor-Induced Gastroduodenitis: An Unusual Manifestation. GE Port J Gastroenterol 2021;28:150-2. [PMID: 33791404 DOI: 10.1159/000509196] [Reference Citation Analysis]
6 Rovedatti L, Lenti MV, Vanoli A, Feltri M, De Grazia F, Di Sabatino A. Nivolumab-associated active neutrophilic gastritis. J Clin Pathol 2020;73:605-6. [PMID: 32161070 DOI: 10.1136/jclinpath-2020-206540] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Isidro RA, Ruan AB, Gannarapu S, Raj D, Rahma O, Grover S, Srivastava A. Medication-specific variations in morphological patterns of injury in immune check-point inhibitor-associated colitis. Histopathology 2021;78:532-41. [PMID: 32931028 DOI: 10.1111/his.14248] [Reference Citation Analysis]
8 Vindum HH, Agnholt JS, Nielsen AWM, Nielsen MB, Schmidt H. Severe steroid refractory gastritis induced by Nivolumab: A case report. World J Gastroenterol 2020;26:1971-8. [PMID: 32390707 DOI: 10.3748/wjg.v26.i16.1971] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
9 Taniguchi S. In Situ Delivery and Production System (iDPS) of Anti-Cancer Molecules with Gene-Engineered Bifidobacterium. J Pers Med 2021;11:566. [PMID: 34204302 DOI: 10.3390/jpm11060566] [Reference Citation Analysis]
10 Demeyer A, Driege Y, Skordos I, Coudenys J, Lemeire K, Elewaut D, Staal J, Beyaert R. Long-Term MALT1 Inhibition in Adult Mice Without Severe Systemic Autoimmunity. iScience 2020;23:101557. [PMID: 33083726 DOI: 10.1016/j.isci.2020.101557] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
11 El-Zimaity H, Riddell RH. Beyond Helicobacter: dealing with other variants of gastritis-an algorithmic approach. Histopathology 2021;78:48-69. [PMID: 33382486 DOI: 10.1111/his.14283] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, Gerber DE, Hamad L, Hansen E, Johnson DB, Lacouture ME, Masters GA, Naidoo J, Nanni M, Perales MA, Puzanov I, Santomasso BD, Shanbhag SP, Sharma R, Skondra D, Sosman JA, Turner M, Ernstoff MS. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 2021;9:e002435. [PMID: 34172516 DOI: 10.1136/jitc-2021-002435] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
13 Johncilla M, Elsoukkary S, Jessurun J. The significance of focally enhanced gastritis in haematopoietic stem cell transplant recipients. Histopathology 2021. [PMID: 33866587 DOI: 10.1111/his.14389] [Reference Citation Analysis]
14 Ebisutani N, Tozawa K, Matsuda I, Nakamura K, Tamura A, Hara K, Kondo T, Terada T, Tomita T, Oshima T, Fukui H, Hirota S, Miwa H. A Case of Severe Acute Gastritis as an Immune-Related Adverse Event After Nivolumab Treatment: Endoscopic and Pathological Findings in Nivolumab-Related Gastritis. Dig Dis Sci 2021;66:2461-5. [PMID: 32780186 DOI: 10.1007/s10620-020-06529-3] [Reference Citation Analysis]
15 Omotehara S, Nishida M, Yamanashi K, Sakurai K, Katsurada T, Komatsu Y, Shimizu A, Shibuya H, Shinagawa N, Sugita J, Teshima T. A case of immune checkpoint inhibitor-associated gastroenteritis detected by ultrasonography. J Clin Ultrasound 2021;49:605-9. [PMID: 33580597 DOI: 10.1002/jcu.22975] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]